We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prognostic Biomarker Detects Acute Kidney Injury

By LabMedica International staff writers
Posted on 08 Aug 2011
A renal injury biomarker in urine or blood detects early subclinical acute kidney injury (AKI) and its adverse outcomes in critically ill patients. More...


Early testing for the biomarker, neutrophil gelatinase-associated lipocalin (NGAL) may therefore allow earlier conventional medical interventions or introduction of novel therapies to improve the prognosis of AKI.

In a retrospective study, involving 13 international medical organizations, data from 2,322 critically ill adult and pediatric patients was pooled. These same patients did not have diagnostic increases in serum creatinine, which is considered the current gold standard for detecting AKI. The critically ill patients whose data was analyzed primarily had Type 1 cardiorenal syndrome, a common condition in which heart dysfunction causes kidney injury.

The scientists recorded that 40% of the patients showed unexpected early increases in urine or blood NGAL levels, but no increases in serum creatinine. These early increases in NGAL concentration had a much greater risk of adverse medical outcomes than patients who tested negative for NGAL. NGAL positive patients were 16 times more likely to need dialysis, three times more likely to die during hospitalization, and on average, they spent three extra days in intensive care and eight extra days in the hospital.

Prasad Devarajan, MD, is one of the lead authors of the study, and a departmental director at Cincinnati Children's Hospital Medical Center, (Cincinnati, OH, USA). He said, "This study describes a new biomarker (NGAL) that completely outperforms the current serum creatinine-based criteria for the early detection of AKI and its devastating clinical outcomes. We concluded that a substantial numbers of patients might reasonably be classified as having subclinical AKI, even though they do not fulfill current creatinine-based criteria for AKI." The researchers now plan to pursue a prospective multicenter study to further verify the effectiveness of the NGAL test as a prognostic biomarker in a large population of patients in critical care settings. The study was published on April 26, 2011, in the Journal of the American College of Cardiology (JACC).

Related Links:

Cincinnati Children's Hospital Medical Center


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.